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Purpose: To investigate the association between dry eye syndrome (DE) and serum levels of interleukin (IL)-17 in 
patients with systemic immune-mediated diseases. 
Methods: IL-17 and IL-23 levels were measured in the sera of patients whose tear production was <5 mm on the 
Schirmer test. Subjects included patients with chronic graft-versus-host disease (GVHD), rheumatoid arthritis 
(RA), Sjogren’s syndrome (SS), systemic lupus erythematosus (SLE), and no systemic disease. Corneal/con-
junctival fluorescein staining was scored and the correlation between the score and the IL-17 level was 
evaluated.
Results: A strong correlation existed between IL-17 level and the type of systemic disease. IL-17 was significantly 
elevated in patients with chronic GVHD compared to those with RA and SS. IL-17 was not detectable in patients 
with SLE or in those without systemic disease. IL-23 was not detected in any of the subjects. IL-17 was sig-
nificantly increased in patients with high fluorescein staining scores.
Conclusions: Our data suggest that IL-17 is involved in the pathogenesis of DE in patients with systemic im-
mune-mediated diseases. 
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Dry eye syndrome (DE) is one of the most important com-
plications of systemic immune-mediated diseases such as 
chronic graft-versus-host disease (GVHD), rheumatoid ar-
thritis (RA), Sjogren’s syndrome (SS), and systemic lupus er-
ythematosus (SLE). All of these disorders are characterized 
by destruction of acinar tissue within the lacrimal glands and 
ocular surface inflammation, which both lead to DE.
Interleukin (IL)-17 is a pro-inflammatory cytokine pro-
duced by a number of human immune cells, including Th17 
cells, neutrophils, and peripheral blood mononuclear cells. 
Recent studies have revealed that IL-17 is upregulated in var-
ious autoimmune inflammatory diseases and is involved in 
the pathogenesis of RA, SS, SLE, and GVHD [1-4]. Regarding 
ocular diseases, an upregulation of IL-17 or IL-23 has been 
observed in patients with uveitis and scleritis [5-7]. IL-23 is 
an essential cytokine for Th17 cell differentiation and func-
tion [8,9]. Also, IL-23 has been shown to be necessary for the 
development of systemic autoimmune diseases such as in-
flammatory bowel disease and collagen-induced arthritis 
[10-12]. These findings suggest that the IL-23/IL-17 path-
way is involved in the development of DE associated with 
systemic immune-mediated diseases. However, the associa-
tion between the IL-23/IL-17 pathway and DE has not been 
established. Given that drugs designed to neutralize IL-23 
and IL-17 are in the pipeline, efforts to elucidate the role of 
those cytokines in DE are worthwhile. Therefore, we per-
formed this study in order to investigate the association be-Korean J Ophthalmol Vol.25, No.2, 2011
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Fig. 1. Levels of interleukin (IL)-17 in sera from dry eye patients 
with systemic diseases and dry eye subjects without systemic dis-
ease (control). GVHD = graft-versus-host disease; RA = rheuma-
toid arthritis; SLE = systemic lupus erythematosus.
Table 1. Clinical and demographic data of dry eye patients enrolled in the study
Total
Combined systemic diseases
Chronic GVHD RA SS SLE None
n 44 8 8 12 6 10
Sex (F:M) 39:5 5:3 8:0 12:0  6:0 8:2
Age (yr) 48.5 ± 23.4 40.8 ± 11.7 47.8 ± 18.5 44.1 ± 22.6 54.0 ± 8.2 55.6 ± 13.9
Fluorescein staining score 4.3 ± 4.5 7.5 ± 2.5 4.0 ± 1.5 5.1 ± 4.5  2.8 ± 4.0 2.0 ± 4.2
GVHD = graft-versus-host disease; RA = rheumatoid arthritis; SS = Sjogren’s syndrome; SLE = systemic lupus erythematosus.
Table 2. Levels of interleukin (IL)-17 in dry eye patients 
with regard to the corneal/conjunctival fluorescein staining 
score
Grade of fluorescein 
staining n IL-17 (pg/mL)
Mild 14 17.5 ± 35.0
Moderate 20 22.3 ± 31.4
Severe 10 93.2 ± 66.8
tween DE and IL-23/IL-17 in DE patients with associated 
systemic immune-mediated diseases. 
Materials and Methods
The patients enrolled in this study had tear production <5 
mm by the non-anesthetic Schirmer test. Subjects included 
patients with chronic GVHD (n = 8), RA (n = 8), SS (n = 
12), SLE (n = 6), and no systemic disease (n = 10). The sys-
temic diseases of the patients were under control with/out 
immunosuppressants. Sera were obtained from peripheral 
blood samples collected from patients without anti-
coagulant agents and stored at ≤-20°C until assay time. The 
serum levels of IL-17 and IL-23 were measured by the 
ELISA method using R&D
  Systems kits (Minneapolis, 
MN, USA) according to the instructions provided by the 
manufacturer. ELISA experiments were performed
 in tripli-
cate to ensure the reproducibility of the data. The lower lim-
its of sensitivity for IL-17 and IL-23 ELISA were 15 pg/mL 
and 4 pg/mL, respectively.
DE severity and ocular surface inflammation were eval-
uated with corneal/conjunctival fluorescein staining. The oc-
ular surface was examined with a slit lamp biomicroscope in 
cobalt blue light, three minutes after fluorescein instillation. 
Punctate staining was recorded with a standardized scoring 
system; the corneal and conjunctival surfaces were divided 
into nine areas and the numbers of stained divisions were 
summed (0 to 9) [13]. Fluorescein staining was graded as 
mild (scores 0 to 3), moderate (4 to 6), or severe (6 to 9). We 
evaluated the correlation between the fluorescein staining 
score and IL-17 level.
Data were expressed as means ± SD and compared using 
the student’s t-test and simple correlation analysis. A p-value 
of <0.05 was considered statistically significant.
Results
The clinical features and demographic data of the patients 
in each group are shown in Table 1. The differences in age 
and sex were not significant among the groups. The IL-17 
levels did not show a significant correlation with patient age 
(p = 0.246).  
Notably, a strong correlation existed between the IL-17 
level and the type of systemic disease (Fig. 1). The IL-17 lev-
el in patients with chronic GVHD was 89.0 ± 30.2 pg/mL, 
which was significantly higher than the level in patients with 
RA (54.0 ± 46.0 pg/mL; p = 0.02) or SS (37.0 ± 46.7 pg/mL; 
p = 0.043). In contrast, IL-17 was not detected in the sera of 
DE patients with SLE or in patients without systemic disease. 
The IL-17 elevation in patients with RA and SS was statisti-
cally significant compared to the levels in patients with SLE 
and those without systemic disease (p = 0.021 and 0.036, re-
spectively). IL-23 was not detected in any of the subjects. 
In addition, IL-17 level was significantly correlated with 
the fluorescein staining score (Table 2). Patients with severe 
fluorescein staining on the ocular surface (defined as staining 
scores 6 to 9) had higher IL-17 serum levels than those with 
moderate or mild fluorescein staining (p = 0.01 and 0.024, 
respectively). 
Discussion
The present study demonstrated that IL-17 production was 
significantly increased in the sera of DE patients with sys-
temic autoimmune diseases, whereas IL-17 was not elevated 
in DE patients without systemic inflammatory co-morbidities. JY Oh, et al. IL-17 in Dry Eye Syndrome
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Interestingly, our study revealed significant IL-17 elevation 
in patients with chronic GVHD. Although there has been a 
study evaluating IL-17 in an acute GVHD animal model 
[14], the present study is, to our knowledge, the first to report 
an association between IL-17 and GVHD in humans. 
In our study, IL-17 level was also associated with the se-
verity of DE, as represented by fluorescein staining scores 
on the ocular surface. Given the fact that patients with 
chronic GVHD had more severe fluorescein staining of 
their eyes, it is possible that severe ocular surface in-
flammation induced IL-17 production and led to the IL-17 
elevation seen in the sera of the DE patients with chronic 
GVHD. However, previous reports have demonstrated that 
IL-17 and Th17 cells are linked to systemic autoimmune 
diseases such as RA and SS in humans [1-5]. Moreover, a 
recent report revealed that IL-17 significantly disrupts the 
corneal epithelial barrier by inducing metalloproteinase 
production on the ocular surface [15]. Taken together, it is 
more likely that increased IL-17 in patients with chronic 
GVHD, RA, or SS induced corneal epithelial barrier dis-
ruption and led to severe DE in our study. 
In our study, IL-23 was not detectable in any of the 
patients. Recent reports have suggested that IL-23 promotes 
IL-17 production by CD4+ T cells and increases suscepti-
bility to autoimmune inflammation [16]. As such, the fact 
that no IL-23 was detected in any of the subjects in this study 
might be related to the fact that our patients’ systemic in-
flammatory diseases were under good control. 
DE is an inflammatory process localized to the ocular sur-
face-lacrimal gland loop [17]. In addition, according to a re-
cent report,
 desiccating stress has been shown to induce a 
Th17 response localized in the cornea and conjunctiva [15]. 
Therefore, evaluation of IL-17 in the lacrimal glands, ocular 
surface, or tears would be valuable in confirming the role of 
IL-17 in DE. We did not perform such studies because lac-
rimal gland biopsy is invasive and the volume of tears that 
can be acquired from DE patients with very low tear pro-
duction is insufficient to perform an ELISA assay. Thus, our 
results do not exclude the possibility that the IL-17 pathway 
is involved in DE in a manner unrelated to systemic im-
mune-mediated disease. In addition, to evaluate the role of 
IL-17 in the pathogenesis of DE, animal studies using an 
IL-17 knockout animal or siRNA would be valuable, as dem-
onstrated by several reports [18].   
Our study is limited in that the number of subjects was not 
sufficient to draw firm conclusions, especially in disorders as 
heterogeneous as GVHD, RA, SS, and SLE. Furthermore, 
the patients in our study were on various immunosuppressant 
medications that could potentially affect serum IL-17 levels. 
Further studies involving a large number of subjects are 
needed. Also, as previously mentioned, the serum level of 
IL-17 may not directly correlate with the level of IL-17 in 
tears. However, we believe our study sheds light on the possi-
ble association between IL-17 and DE. 
In conclusion, our study showed that IL-17 was elevated in 
DE patients with chronic GVHD, RA, and SS. It also showed 
that IL-17 elevation was more significant in DE patients with 
severe fluorescein staining on the ocular surface. All these 
results suggest that the IL-17 pathway is involved in the 
pathogenesis of DE associated with systemic inflammatory 
diseases. Drugs designed to neutralize IL-17 are in the pipe-
line, and they have proven to be effective in treating RA. 
Hence, further studies on the role of IL-17 in DE will provide 
new strategies for the treatment of DE. 
Conflict of Interest
No potential conflict of interest relevant to this article was 
reported.
References 
  1.Nguyen CQ, Hu MH, Li Y, et al. Salivary gland tissue ex-
pression of interleukin-23 and interleukin-17 in Sjogren’s syn-
drome: findings in humans and mice. Arthritis Rheum 2008; 
58:734-43.
  2.Sakai A, Sugawara Y, Kuroishi T, et al. Identification of IL-18 
and Th17 cells in salivary glands of patients with Sjogren’s 
syndrome, and amplification of IL-17-mediated secretion of 
inflammatory cytokines from salivary gland cells by IL-18. J 
Immunol 2008;181:2898-906.
  3.Garrett-Sinha LA, John S, Gaffen SL. IL-17 and the Th17 line-
age in systemic lupus erythematosus. Curr Opin Rheumatol 
2008;20:519-25.
  4.Tesmer LA, Lundy SK, Sarkar S, Fox DA. Th17 cells in hu-
man disease. Immunol Rev 2008;223:87-113.
  5.Chi W, Zhu X, Yang P, et al. Upregulated IL-23 and IL-17 in 
Behçet patients with active uveitis. Invest Ophthalmol Vis Sci 
2008;49:3058-64.
  6.Amadi-Obi A, Yu CR, Liu X, et al. TH17 cells contribute to 
uveitis and scleritis and are expanded by IL-2 and inhibited by 
IL-27/STAT1. Nat Med 2007;13:711-8.
    7.Abraham C, Cho J. Interleukin-23/Th17 pathways and in-
flammatory bowel disease. Inflamm Bowel Dis 2009;15:1090-100.
  8.Diveu C, McGeachy MJ, Cua DJ. Cytokines that regulate 
autoimmunity. Curr Opin Immunol 2008;20:663-8.
  9.McGeachy MJ, Chen Y, Tato CM, et al. The interleukin 23 re-
ceptor is essential for the terminal differentiation of inter-
leukin 17-producing effector T helper cells in vivo. Nat 
Immunol 2009;10:314-24.
10.Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives 
a pathogenic T cell population that induces autoimmune in- 
flammation. J Exp Med 2005;201:233-40.
11. Yen D, Cheung J, Scheerens H, et al. IL-23 is essential for T 
cell-mediated colitis and promotes inflammation via IL-17 
and IL-6. J Clin Invest 2006;116:1310-6.
12.Murphy CA, Langrish CL, Chen Y, et al. Divergent pro- and 
antiinflammatory roles for IL-23 and IL-12 in joint auto-
immune inflammation. J Exp Med 2003;198:1951-7.
13.Norn MS. Lissamine green. Vital staining of cornea and 
conjunctiva. Acta Ophthalmol (Copenh) 1973;51:483-91.
14.Kappel LW, Goldberg GL, King CG, et al. IL-17 contributes to 
CD4-mediated graft-versus-host disease. Blood 2009;113:945-52.
15.De Paiva CS, Chotikavanich S, Pangelinan SB, et al. IL-17 
disrupts corneal barrier following desiccating stress. Mucosal 
Immunol 2009;2:243-53.
16.Sutton CE, Lalor SJ, Sweeney CM, et al. Interleukin-1 and Korean J Ophthalmol Vol.25, No.2, 2011
76
IL-23 induce innate IL-17 production from gammadelta T 
cells, amplifying Th17 responses and autoimmunity. Immunity 
2009;31:331-41.
17.Mathers WD. Why the eye becomes dry: a cornea and lacrimal 
gland feedback model. CLAO J 2000;26:159-65.
18.Chauhan SK, El Annan J, Ecoiffier T, et al. Autoimmunity in 
dry eye is due to resistance of Th17 to Treg suppression. J 
Immunol 2009;182:1247-52.